ADIAL PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $16.73M
- P/E (TTM)
- –
- Dividend yield
- –
About Adial Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment or prevention of addiction and related disorders. Its primary investigational drug candidate is AD04, a therapeutic agent designed to treat alcohol use disorder (AUD). The company develops this treatment alongside a companion diagnostic genetic test to identify and target patients with specific genotypes. Adial has no approved products and focuses its resources on research, development, and clinical evaluation.
The company operates in the United States and has conducted clinical investigations across six European countries, including Sweden, Finland, Poland, Latvia, Bulgaria, and Croatia. It also pursues strategic partnerships to support potential commercialization in Europe. Adial maintains its principal executive offices in Glen Allen, Virginia.
Summary of the business section of Adial Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ADIAL PHARMACEUTICALS, INC.
- Headquarters
- Charlottesville, VA
- Address
- 1180 Seminole Trail, Suite 495 22901
- Phone
- (434) 422-9800
- Website
- adial.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, Marlton, New Jersey
Stock & identifiers
- Ticker
- ADIL
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2018
- Shares outstanding
- 3M, Aug 12, 2026
- Public float
- $6.48M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Mar 5, 2026; 1-for-25 reverse, Feb 6, 2026; 1-for-25 reverse, Aug 21, 2023; 1-for-25 reverse, Aug 7, 2023
- SEC CIK
- 1513525
- CUSIP
- 00688A304
- ISIN
- US00688A3041
- EIN
- 80-0667150
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matt Davidson | Chief Development Officer, Director | 302,841 |
| Tony Goodman | Chief Operating Officer, Director | 26,523 |
| Cary J. Claiborne | Chief Executive Officer, Director | 40,417 |
| Vinay Shah | Chief Financial Officer | 17,325 |
| Wendy B. Young | Director | – |
| J. Kermit Anderson | Director | – |
| Kevin Schuyler | Director | 9,447 |
| Robertson H. Gilliland | Director | 104,609 |
| James W. Newman Jr. | Director | 338,463 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Cary Claiborne | $890.65K | $600.17K | $464.41K | $4 | – |
| FY2024 Cary Claiborne | $976.34K | $823.53K | $352.31K | $19 | – |
| FY2023 Cary Claiborne | $801.62K | $575.60K | $412.02K | $35 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Form 10-K, we have six employees, of which five are full-time employees, and one is a consultant.”
Corporate history
Events identified from SEC filings